{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:50:27Z","timestamp":1787064627293,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.leukres.2024.107480","type":"journal-article","created":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T21:49:57Z","timestamp":1710193797000},"page":"107480","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study"],"prefix":"10.1016","volume":"140","author":[{"given":"Guillermo","family":"Garcia-Manero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Kazmierczak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Wierzbowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun Yew","family":"Fong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Keng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Ballinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lionel","family":"Ad\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2024.107480_bib1","series-title":"Acute Myelogenous Leukemia","first-page":"1183","author":"Liesveld","year":"2005"},{"key":"10.1016\/j.leukres.2024.107480_bib2","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/cncr.22233","article-title":"Acute myeloid leukemia: epidemiology and etiology","volume":"107","author":"Deschler","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.leukres.2024.107480_bib3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.leukres.2024.107480_bib4","unstructured":"National Cancer Institute. SEER 22, 2015-2019. Cancer Stat Facts: Acute Myeloid Leukemia (AML). 2022. Available at \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/amyl.html\u3009. Accessed May 2022."},{"issue":"5","key":"10.1016\/j.leukres.2024.107480_bib5","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/j.1365-2141.2010.08470.x","article-title":"Acute myeloid leukemia in the elderly: a review","volume":"152","author":"Pollyea","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107480_bib6","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","article-title":"Age and acute myeloid leukemia","volume":"107","author":"Applebaum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107480_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2010.1.62","article-title":"Treating the elderly patient with acute myelogenous leukemia","author":"Luger","year":"2010","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"issue":"3","key":"10.1016\/j.leukres.2024.107480_bib8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107480_bib9","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"New Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2024.107480_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J."},{"issue":"24","key":"10.1016\/j.leukres.2024.107480_bib11","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2024.107480_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0012197","article-title":"DNA methylation profiles and their relationship with cytogenetic status in adult acute myeloid leukemia","volume":"5","author":"Alvarez","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.leukres.2024.107480_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2005.01.006","article-title":"The fundamental role of epigenetics in hematopoietic malignancies","volume":"20","author":"Galm","year":"2006","journal-title":"Blood Rev."},{"key":"10.1016\/j.leukres.2024.107480_bib14","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood.V97.9.2823","article-title":"Methylation profiling in acute myeloid leukemia","volume":"97","author":"Toyota","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2024.107480_bib15","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"issue":"Suppl.","key":"10.1016\/j.leukres.2024.107480_bib16","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.seminhematol.2005.05.002","article-title":"Pharmacology of 5-Aza-2\u2019deoxycytidine (decitabine)","volume":"42","author":"Momparler","year":"2005","journal-title":"Semin Hematol."},{"issue":"20","key":"10.1016\/j.leukres.2024.107480_bib17","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1007\/s00018-014-1656-6","article-title":"Histone deacetylase inhibitors and cell death","volume":"71","author":"Zhang","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.leukres.2024.107480_bib18","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.leukres.2024.107480_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1172\/JCI69738","article-title":"New and emerging HDAC inhibitors for cancer treatment","volume":"124","author":"West","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.leukres.2024.107480_bib20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/5047","article-title":"Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer","volume":"21","author":"Cameron","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2024.107480_bib21","first-page":"557","article-title":"Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors","volume":"10","author":"Schneider-Stock","year":"2007","journal-title":"IDrugs"},{"key":"10.1016\/j.leukres.2024.107480_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/bjh.13016","article-title":"A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome","volume":"167","author":"Kirschbaum","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.leukres.2024.107480_bib23","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3109\/10428194.2015.1018248","article-title":"A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia","volume":"56","author":"How","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.leukres.2024.107480_bib24","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u226430% blasts","volume":"31","author":"Garcia-Manero","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2024.107480_bib25","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1002\/cncr.30949","article-title":"Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies","volume":"123","author":"Abaza","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2024.107480_bib26","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1200\/JCO.2013.50.3102","article-title":"Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: Results of the US Leukemia intergroup trial E1905","volume":"32","author":"Prebet","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107480_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/cncr.29085","article-title":"Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia","volume":"121","author":"Issa","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2024.107480_bib28","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1200\/JCO.2006.09.4169","article-title":"Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia","volume":"25","author":"Blum","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.leukres.2024.107480_bib29","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1182\/blood-2006-03-009142","article-title":"Phase 1\/2 study of the combination of 5-aza-2\u2019-deoxycytidine with valproic acid in patients with leukemia","volume":"108","author":"Garcia-Manero","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2024.107480_bib30","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study","volume":"3","author":"Garcia-Manero","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2024.107480_bib31","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.30533","article-title":"Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes","volume":"123","author":"Garcia-Manero","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.leukres.2024.107480_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2012.14","article-title":"The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML","volume":"2","author":"Novotny-Diermayr","year":"2012","journal-title":"Blood Cancer J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212624000468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T09:02:25Z","timestamp":1714640545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212624000468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":32,"alternative-id":["S0145212624000468"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107480","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2024.107480","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107480"}}